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Abstract  
Therapeutic tolerance restoration has been proven to modify food allergy in patients and 
animal models and although sublingual immunotherapy (SLIT) has showed promise, 
combined therapy may be necessary to achieve a strong and long-term tolerance. In this 
work, we combined SLIT with systemic administration of IL-2 associated with an anti-IL-2 
monoclonal antibody (IL-2/anti-IL-2Ab complex or IL-2C) to reverse the IgE-mediated 
experimental allergy. 
Balb/c mice were sensitized with cholera toxin and milk proteins and orally challenged with 
allergen to elicit hypersensitivity reactions. Then, allergic mice were treated with a sublingual 
administration of very low amounts of milk proteins combined with  intraperitoneal injection 
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of low doses of IL-2C. The animals were next re-exposed to allergens and mucosal as well as 
systemic immunological parameters were assessed in vivo and in vitro. 
The treatment reduced serum specific IgE, IL-5 secretion by spleen cells and increased IL-10 
and TGF-β in the lamina propria of buccal and duodenal mucosae. We found an augmented 
frequency of IL-10-secreting CD4+CD25+Foxp3+ regulatory T cells (Treg) in the submaxilar 
lymph nodes and buccal lamina propria. Tregs were sorted, characterized and adoptively 
transferred to naïve mice, which were subsequently sensitized. No allergy was experienced in 
these mice and we encouragingly discovered a faster and more efficient tolerance induction 
with the combined therapy compared with SLIT. 
In conclusion, the combination of two therapeutic strategies rendered Treg-mediated 
tolerance more efficient compared to individual treatments and reversed the established IgE-
mediated food allergy. This approach highlights the ability of IL-2C to expand Tregs, and it 
may represent a promising disease-modifying therapy for managing food allergy. 
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Introduction 
Cow’s milk allergy (CMA) has evolved as an emerging  epidemic during the last decades 
(1,2). The allergy is mediated by adaptive immune responses characterized by a Th2-skewed 
T cell response (3,4) that drives high IgE secretion which may result in the risk of life-
threatening anaphylaxis in a proportion of allergic patients (5). One of the potential causes of 
this aberrant immune response to harmless dietary antigens has been attributed to a failure to 
induce regulatory T cell (Treg)-mediated tolerance (6–8). Patients suffering from 
polyendocrinopathy X-linked syndrome (IPEX) have a deficit in Tregs due to a mutation of 
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the FOXP3 gene, causing a loss of tolerance with subsequent severe autoimmunity, food 
allergy and infection (9). In addition, Foxp3 polymorphism and differential epigenetic control 
of gene expression have been described in food allergic patients (10–12). Remarkably, 
induction of Tregs is a critical marker of spontaneous resolution of food allergy (8,13) and of 
successful specific disease-modifying  immunotherapy (14,15). We have previously 
demonstrated in an IgE-mediated food allergy mouse model, (that closely recapitulates food 
allergy in humans), that Tregs are reduced in sensitized animals and the adoptive transfer of 
these cells reversed mucosal inflammation and allergic immune responses (16). We observed 
that the step-wise oral administration of cow´s milk proteins (CMP) to sensitized mice 
induced intestinal Tregs, which suppressed the Th2-mediated mechanisms (including IgE, 
cytokines, skin mast cell activation).and the clinical symptoms. Based on these findings, we 
were prompted to down-modulate clinical signs by sublingual administration of very low 
doses of CMP, compared to the doses administered by gavage. 
 
A recent therapeutic approach for several immunological diseases (autoimmunity, GVHD, 
etc) has been the in vivo or ex vivo expansion and transfer of Tregs (17–20) using low doses 
of the T cell growth factor IL-2 (21,22). It has been therapeutically used in immunological 
disorders in human and experimental models (23–27) with differing degrees of success . 
(28,29). Low doses of IL-2 increased in vivo the frequency of Tregs expressing the high 
affinity IL-2 receptor (IL-2R) (30), and different strategies have been investigated to optimize 
its bioavailability (31–33).  In a pilot study using low doses of human IL-2 (25000 IU), along 
with sublingual immunotherapy (10 ng of allergen), we failed to suppress hypersensitivity 
symptoms in animals that were intragastrically sensitized (unpublished results). Based on the 
fact that particular high affinity anti-IL-2 monoclonal antibody improves IL-2 bioavailability 
and targets IL-2 (preferentially to CD25 on Tregs) (34,35,45), we next assessed the 
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therapeutic potential of low doses of IL-2 (15000 IU) combined with the monoclonal 
antibody (IL-2/anti-IL-2 complex; IL-2C) in the experimental model of food allergy. We 
found that the intraperitoneal administration of IL-2C successfully enhanced the tolerogenic 
mechanisms induced by very low doses of sublingual antigen and reversed food allergy. 
 
Materials & Methods 
Reagents 
Milk protein extract was prepared from skimmed dry milk (Svelty, Nestle). CMP were 
dissolved in PBS for sublingual administration or in buffer bicarbonate for oral 
administration. Cholera toxin (CT) (Sigma Aldrich, St. Louis, USA), used as mucosal 
adjuvant, was dissolved in bicarbonate buffer (14). IL-2C was prepared by mixing IL-2 
(15000IU) (Proleukin, Novartis, San Diego, CA, USA) with anti-IL-2 (4.5µg) (clone 5344, 
BD, NJ, USA) at a 2:1 molar ratio and incubated 30 minutes at 37ºC before injected in the 
mice.  
 
Animals, sensitization and challenge 
For sensitization, 5- to 7-week old BALB/c male mice received 6 weekly intragastric (ig) 
doses of 20 mg of CMP and 10 μg of CT in 200 µl per mouse (n = 5/group) (16). Ten days 
after the final boost, mice were challenged by gavage with 10 mg of CMP in 200 µl on two 
consecutive days (2 intragastric challenges). Twenty-four hours later animals were sacrificed 
by cervical dislocation. Control group mice received 20mg CMP (without CT) during the 
sensitization phase. The experimental design is shown in Fig. S1.  
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Animal treatment 
Sensitized mice were anesthetized and divided into 2 groups for sublingual (sl) treatment: a) 
mice receiving PBSsl and b) mice receiving 10 pg/4 µl of CMPsl twice a week during four 
weeks and 10 ng during the last four weeks. Groups were further divided in 2 sub groups for 
intraperitoneal treatment: i) mice receiving PBSip and ii) mice receiving IL-2C ip (Fig. S1). 
Thirty minutes after the sl administration mice were grouped and placed in clean cages to 
assure no cross-contamination between animals. 
To characterize the mucosal induction of Tregs, mice received 175µg/4µl of CMPsl or PBSsl 
for 2 consecutive days, and thereafter they received intraperitoneal injections of IL-2C for 3 
consecutive days. Finally, mice were sacrificed (day 5) and submaxilar lymph nodes (SLN) 
and sublingual mucosa were analyzed.  
 
Ethics statement 
All protocols were approved by the Institutional Committee for the Care and Use of 
Laboratory Animals of the School of Sciences (University of La Plata) (Protocol Number: 
017-00-15). 
 
In vivo evaluation of the allergic reaction 
Clinical symptoms. Symptoms were observed 15-45 min following the second intragastric 
challenge in a blind fashion by 2 independent investigators. Clinical scores are as follows: 0= 
No symptoms; 1= Scratching and rubbing around the snout and head; 2= Puffiness around the 
eyes and mouth, pilo-erection, reduced activity and/or decreased activity with increased 
respiratory rate; 3= Hyperreactivity followed by respiratory distress, cyanosis around the 
snout and tail; 4= No activity upon stimuli, convulsion; 5= Death. Death of mice is 
infrequently observed since it is not an anaphylaxis model. 
Cutaneous tests. Mice were injected with 20 μg of CMP in 20 μl of sterile saline in one 
footpad, and saline in the contra-lateral footpad (negative control), and later were injected 
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intravenously (iv) with 100 μl of 0.1% Evans blue dye (Anedra, Buenos Aires, Argentina). 
The presence of blue color 10–20 min after the iv injection was considered a positive test and 
footpad swelling was measured with a digital micrometer.  
In vitro evaluation of the allergic reaction 
Serum specific antibodies. CMP-specific IgE was measured by EAST as previously described 
(36). All samples were run in the same experiment.  
Cytokine quantification. Splenocytes (4x106 spleen cells/ml) were seeded in 96-well cell 
culture plates in complete medium (RPMI-1640 supplemented with 10% FBS, 100U/ml 
penicillin and 100μg/ml streptomycin) and stimulated with CMP (350μg/ml) for 72 h at 37ºC 
in controlled atmosphere. Cytokines (IL-5, IFN-γ) were measured in supernatants by ELISA 
(eBioscience, San Diego, CA, USA) following the manufacturer´s instructions (16).  
Cytokine quantification in tissues. Harvested gut and sublingual mucosa were immediately 
frozen in liquid nitrogen and stored at -80°C. Sections of tissues were weighed, minced and 
treated with lysis buffer (10mM Tris-HCl, 150mM NaCl, 1% NP-40, 10% Glycerol, 5 mM 
EDTA and a protease inhibitor cocktail-Sigma). Homogenates were sonicated, spinnedand 
the supernatant was collected. IL-10 and TGF-β were determined by ELISA (eBioscience) 
following the manufacturer´s instructions. 
Cell isolation from gut and sublingual mucosa. Cells were isolated from the lamina propria 
(LP) of the oral mucosa or small bowel as described by Di Sabatino et al. (37). In brief 
summary, the epithelial compartment was removed by incubation with HBSS and 1mM 
EDTA, followed by treatment with 1mg/ml of collagenase A (Roche, IN, USA) and 10U/ml 
of DNAse in complete RPMI-1640 medium. Cell debris was removed by filtration and finally 
cells from submaxilar lymph nodes (SLN) were obtained by digestion with collagenase in 
RPMI medium for 30 minutes at 37°C.  
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Flow cytometry for cell characterization. SLN and LP cells were stained using anti-CD4 
(PerCyP 5.5), anti-CD25 (PE or FITC) and anti-α4β7 (APC) (eBioscience, UK). For 
intracellular staining, cells were washed, pre-incubated with fixation/permeabilization 
solution (eBioscience, UK) for 20 min at 4°C, then incubated with the Staining Intracellular 
kit (eBioscience, UK), anti-FoxP3 (APC or PE) or anti-IL-10 (APC) (eBioscience, UK). For 
intracytoplasmatic cytokine staining, cells were stimulated with mouse rIL-2 (20 ng/ml, 
Preprotech, NJ, USA) for 12 h at 37°C and 3 μg/ml of Brefeldin A (eBioscience, UK) for the 
last 4 h of cell culture. Fluorescence acquisition was performed with a FACScalibur 
cytometer using QuestProCell software. The gating strategy for cell analysis consisted of a 
lymphocyte gate based on SSC-H vs FSC-H parameters, followed by SSC-H vs CD4 
fluorescence; CD4+ lymphocyte subset was further gated as CD25 vs FoxP3, and 
CD4+CD25+FoxP3+ cells were gated as FoxP3 vs IL-10 or α4β7. Finally, data was analyzed 
with FlowJo software. 
Gating strategy for dendritic cell characterization was as follows: First we plotted SSC-H vs 
FSC-H followed by S CD11c vs MHC II I-A/I-E (eBioscience, UK) dot plot. 
 Treg purification and transfer to naïve mice. Donor CD4+ cells were purified from SLN of 
treated (PBSsl or CMPsl + IL-2 C) mice using the CD4+ T cells isolation kit (BD, Pharmigen, 
USA), followed by the sorting of CD4+CD25+CD62L+ and CD4+CD25+CD62L- cells in a 
FACSAria II (BD, USA). The purity of sorted cells was evaluated by flow cytometry and 
characterized as IL-10-, FoxP3- or α4β7-expressing cells. A total of 1x105 Treg were 
intravenously transferred into naïve recipient mice, which were then orally sensitized with 
CMP + CT during a 4-week period. Seven days following the last boost mice were 
challenged by gavage with CMP and hypersensitivity symptoms were recorded with an 
accompanying skin test also being carried as described (16). 
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Ex vivo suppression assay. Suppressor activity of sorted Tregs was assessed by inhibiting cell 
proliferation (carried out by the CFSE dilution method). Spleen mononuclear cells (1x105 
cells) used as responder were labeled with 3µM CFSE (Invitrogen, Carlsbad, CA, USA) and 
cultured with highly purified unlabeled CD4+CD25+CD62L+ T cells or CD4+CD25-CD62L+ 
T cells at decreasing responder: suppressor cell ratios (4:1, 8:1, 16:1, and 32:1). Responder 
cells were stimulated with anti-CD3/CD28 Abs (eBioscience, UK) and complete medium. 
Proliferation of CFSE-labeled cells was assessed by flow cytometry after 4 days of culture. 
 
Statistical analysis 
Experimental values were expressed as means ± SD and statistical significances between 
groups were evaluated using Mann-Whitney U test, or ANOVA followed by post hoc 
analysis with Bonferroni or Dunn´s comparison test. P values were considered significant if 
p< 0.05; p< 0.01; p< 0.001 and analysis was performed using GraphPad 5 software (San 
Diego, CA). 
 
Results 
Administration of IL-2C ameliorates symptoms and reduces skin mast cell degranulation in 
sensitized mice 
We tested the effect of the sublingual administration of CMP, CMPsl, IL-2 ip and CMPsl 
combined with IL-2Cip in IgE-sensitized mice. After the second oral challenge to the 
sensitized mice we observed a high clinical score (Fig. 1A) and a positive skin test (Fig. 1B 
and C), thus suggesting the induction of IgE and activation of sensitized cells. Then, 
sensitized animals (from now referred as CMP+CT) received treatments for two months. 
After the first round of treatment, all the mice showed significantly lower clinical scores 
compared to the sensitized mice that received PBS as; CMPsl+IL-2Cip (combined SLIT) 
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proved the most effective (p<0.001). In addition, combined SLIT reduced symptoms more 
efficiently than SLIT (p<0.05). Following the second round of treatments, combined SLIT 
again proved the most efficient treatment compared to the sensitized mice that were 
administered with PBS and those mice also showed less intense skin test and swelling of 
footpads. No significant improvement regarding clinical scores was observed between the 
first and second round of treatment with CMPsl+IL-2Cip. As control, animals that received 
only CMP during the complete protocol did not show any hypersensitivity or sensitization 
(Control Ag group). These findings demonstrated that sensitized mice that received the 
combined SLIT reduced in the clinical score (p<0.05), skin test and foot swelling (p<0.01) 
faster and more efficiently than mice that received only SLIT. 
 
Systemic Th2 immune response is effectively suppressed with treatments 
To elucidate on the immunological response that mediates the control of food allergy, Th2-
mediated mechanisms were analyzed. We first observed that CT-driven sensitization to CMP 
induced a significant increase of serum CMP-specific IgE, which was reversed after the first 
round of treatment (day 76) with CMPsl (p<0.05) and CMPsl+IL-2Cip (p<0.01) (Fig. 1D). 
Furthermore we observed that IL-2C alone did not suppress IgE secretion after the first round 
of treatment. Nevertheless, the analysis of serum specific IgE after the second round of 
treatments (day 110) revealed a significant reduction of antibody secretion with all 
treatments, CMPsl+IL-2Cip being the most efficient desensitization protocol. Moreover, IL-5, 
a prototype type 2 cytokine, was substantially inhibited from spleen cells in animals treated 
with IL-2C and CMPsl+IL-2Cip (p<0.001), and it was suppressed with CMPsl (p<0.01) after 
the first round of treatment. The second round of treatment sustained the inhibition of IL-5 
secretion with CMPsl+IL-2Cip, whereas CMPsl induced a more profound effect (Fig. 1E). 
Controls showed no induction of splenocyte IL-5 secretion in mice that received CMP, 
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whereas high levels of the cytokine were detected in the supernatants of cells from sensitized 
mice (administered with PBSsl). No changes in IFN-J levels were observed in all conditions 
(data not shown). These findings suggest a more effective attenuation of the Th2-sensitization 
in allergic mice when treated with combined SLIT.  
 
Treatments induced regulatory cytokines and Tregs in the intestinal lamina propria 
To understand the clinical control of sensitized mice with treatments, we analyzed the 
intestinal level of tolerogenic cytokines and we found a significant increase in IL-10 and 
TGF-β in mice treated with CMPsl+IL-2Cip (2 rounds) compared to control mice (sensitized 
mice that received PBS) (Fig. 2A). We observed that treatment with IL-2C did not induce an 
increase in TGF-β, and SLIT led to a significant up-regulation of IL-10 and TGF-β, although 
symptoms were not reduced. Notably, IL-2C alone induced IL-10 secretion. After the second 
round of treatments combined SLIT induced higher levels of intestinal IL-10 and TGF-β 
compared to SLIT (p<0.05). Assessment of cell frequency in the intestinal LP revealed that 
CD4+ cells was increased for CD25+FOXP3+ cells in mice that received CMPsl+IL-2C after 2 
rounds of treatment (figure 2B), compared to sensitized mice that received PBS or CMPsl 
(p<0.05). The combined SLIT induced a 5.15 and 2.45 fold-increase of CD4+CD25+FOXP3+ 
cells compared to sensitized mice and SLIT, respectively. These findings showed that the 
combined SLIT induced more efficiently Tregs and tolerogenic intestinal cytokines compared 
to SLIT. 
 
The therapeutic control of food allergy correlated with the induction of Tregs in the oral 
mucosa  
To elucidate whether SLIT and combined treatment induced Tregs in the oral mucosa, we 
assessed the frequency of CD4+CD25+FOXP3+ cells in the SLN and sublingual mucosa. We 
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found an increase of Tregs in SLN (p<0.01) in sensitized mice that received CMPsl+IL-2C 
(Fig. 2C), whereas no increase was observed after SLIT, neither in SLN nor in the buccal 
mucosa. Interestingly, sensitized animals that received CMPsl showed the highest amount 
(12.7±0.8%) of IL-10-producing CD4+CD25+FOXP3+ T cells (p<0.01) in the SLN compared 
to other treatments (Fig. 2D). We could not document an induction in TGF-β-producing 
Tregs neither in the SLN nor in the buccal lamina propria (not shown). The combined 
treatment showed the highest frequency of CD4+CD25+FOXP3+ cells in the buccal mucosa 
following the whole treatment, compared to sensitized animals (p<0.01), indicating that these 
cells accumulated in this tissue (Fig. 2E). We also examined other cell subsets in the buccal 
mucosa and we found that the I-A/I-EhighCD11c+ cells (comprising conventional and 
inflammatory DCs (38)), lost the MHC expression with all treatments (p<0.001). The 
frequency of I-A/I-EhighCD11c+ cells was 7.1±3.1% in sensitized mice that received PBSsl, 
3.2±0.3% in sensitized mice treated with CMPsl, 1.4±0.1% of mice treated with IL-2Cip and 
1.1±0.1% in mice treated with CMPsl+IL-2Cip (Fig 3A). Interestingly, the abrogation of I-A/I-
EhighCD11c+ myeloid cells was specific of the buccal mucosa (Fig. 3B).  
 
The protective effect of CMP+IL-2C treatment initiated in the oral mucosa and correlated 
with the induction of suppressive Tregs 
In assessing the immunological mechanism underlying the suppression of food allergy, a 
treatment with CMPsl+IL-2Cip was designed to purify and characterize Tregs (Fig. 4A). We 
observed that 2 administrations of CMPsl followed by 3 systemic boosters with IL-2Cip 
increased IL-10 and TGF-β levels in the buccal lamina propria, compared to control mice 
only receiving PBS sl+IL-2Cip (Fig. 4B). After CD4+CD25+CD62L+ and CD4+CD25-CD62L+ 
cells were sorted from SLN of mice treated with CMPsl+IL-2C (figure 4C), we found that the 
frequencies of cells expressing IL-10, FOXP3+ and surface α4β7+ were significantly 
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increased in CD4+CD25+CD62L+ cells, but not in those from mice that received PBSsl+IL-
2Cip (not shown). Finally, the functional role of sorted cells was examined in vitro and in 
vivo. Figure 5A and B show cell proliferation of responder CFSE-labeled CD4+ T cells from 
untreated mice (activated with anti-CD3/anti-CD28), and co-cultured with SLN sorted cells. 
The staining of CFSE demonstrated that proliferation of responder cells was maximum with 
medium (i), not suppressed by CD4+ T cells from untreated mice (ii), or by CD4+CD25-
CD62L+ from mice receiving CMP+IL-2C (iii); whereas CD4+CD25+CD62L+ cells from 
CMP+IL-2C-treated mice suppressed up to a responder:suppressor cell ratio of 4:1 (only this 
condition is depicted) (iv); responder:suppressor ratio of 32:1 with no effect (v) (Figure 5A 
and Fig. 5B). Moreover, sorted CD4+CD25+CD62L+ and CD4+CD25-CD62L+ cells from 
mice that received PBS+IL-2Cdid not exert any inhibitory effect at the same cell ratios (not 
shown).  
To test the importance of sorted cells in vivo, CD4+CD25-CD62L+ or CD4+CD25+CD62L+ 
cells (105) were adoptively transferred into naïve mice, which were then sensitized with 
CT+CMP (Fig. 5C). After the intragastric challenge, animals transferred with 
CD4+CD25+CD62L+ cells showed a lower clinical score and a weaker skin test, with reduced 
footpad swelling compared to animals injected with CD4+CD25-CD62L+ cells or PBS (Fig. 
5D and E). This led us to conclude that the therapeutic intervention with the combined 
therapy induces CD4+CD25+CD62L+ cells in SLN of sensitized mice, which exerts a 
suppressor effect and in turn controls the allergic reaction. 
 
Discussion 
Genetic and immunological evidence proposes that the pathogenesis of allergic disease is 
closely related with a breakdown in oral tolerance to foods. The expansion of Tregs balances 
the immune system, restraining the specific Th2 cell response at mucosal sites (39). 
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Currently, interesting research is being focused on developing therapies that modify the 
allergic immune response through the restoration of tolerance in patients (40,41). The oral 
allergen specific approach seems to be promising with a recent study that compared oral and 
sublingual immunotherapies showing that the controlled sublingual administration of 
allergens is safer, although less effective, compared to oral immunotherapy (42,43). Although 
SLIT has proven to be clinically effective in asthma and rhinoconjunctivitis, in food allergy it 
has been proposed the allergen should be administered accompanied with a pro-tolerogenic 
adjuvant for the induction of robust tolerance (44). Another therapeutic option is combined 
therapies. Bonnet et al. recently showed that a low-dose IL-2 (50,000IU) regime controlled 
experimental food allergy through the induction of Tregs (45). Systemically sensitized mice 
were given human IL-2 in a preventive treatment protocol and the intestinal expansion of 
CD4+ and CD8+ FOXP3+ Tregs controlled anaphylaxis upon allergen challenge. Again, an 
alternative strategy was explored by Wilson et al., who reported that human IL-2 complexed 
with an anti-IL-2 mAb (clone JES6-1A12) reduced lung inflammation, eosinophilia and 
bronchial hyperreactivity in experimental asthma, with an increase of tissue IL-10-producing 
Treg (46). Similar to us, they found no beneficial effect with the administration of IL-2 on 
airway inflammation. In our mouse model of intragastric sensitization, hypersensitivity 
reactions were evidenced following two intragastric challenges. Treated animals showed that 
the most effective therapeutic procedure consisted in the sublingual administration of very 
low doses of allergen (10 pg and 10 ng of CMP per administration) combined with low doses 
of IL-2 (15000 IU/injection) complexed with anti-IL-2. We observed that the combined 
therapy reversed the Th2-mediate immune response, along with the expansion of Treg cells in 
the buccal mucosa, thus meaning that the antigen is absorbed (Although we cannot evidence 
that mice retained the allergen under the tongue for a period). Our results suggest that the 
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combined immunotherapy can improve the safety and efficacy of the sublingual therapy and 
hopefully create further clinical opportunities for new treatment in food allergy.  
As IL-2C was here shown to be more effective at inducing Tregs when the antigen was 
administered at the buccal mucosa compared with PBS administration, the combined use of 
antigen and IL-2C seems to promote immune tolerance compared to antigen or IL-2C alone. 
Moreover, our findings highlight the functional role of buccal-induced Tregs, which favored 
a mucosal environment that restored intestinal tolerance, and thus nullifying the side effects 
that might occur with the intragastric allergen challenge. Remarkably, as Tregs are reduced in 
sensitized mice both at the buccal mucosa (14.4±1.7%) and intestinal lamina propria 
(13.6±0.9), compared with mice treated with the combined therapy (93.3±1.7% vs 56.7±2.3% 
cells, respectively). The tolerogenic environment induced at the buccal mucosa promoted a 
significant reduction in the frequency of the pro-inflammatory DC-expressing 
CD11c+MHCII+.(7.1±3.1% vs 1.1±0.1% cells in sensitized and treated mice, respectively) 
(p<0.05). The frequency of intestinal DC-bearing CD11c+MHC II+ remained statistically 
unchanged (11.6±0.8 vs 8.1 0.1% cells in sensitized and treated mice, respectively). In 
addition, the SLN-induced α4β7-expresing CD4+CD25+CD62L+Foxp3+ Tregs migrated to the 
gut and induced the local production of IL-10 and TGF-β. This tolerogenic environment 
controlled the intestinal and systemic Th2-biased allergic immune reaction. 
In conclusion, we have improved the SLIT treatment using very low amounts of allergen 
through the mucosal route combined with the systemic administration of Treg cell-expanding 
IL-2C, which proved to be efficient to reverse IgE-mediated experimental food and this 
combined therapy may represent a promising treatment for managing food allergy.  
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Legends to figures 
Figure 1. In vivo and in vitro immune response to oral CMP administration in the food 
allergy mouse model. A. Clinical scores corresponding to symptoms elicited following the 
intragastric challenges (at the end of the first and second rounds of treatments) with CMPs. B. 
Skin tests; control Ag corresponds to animals that were administered with CMP only (not 
sensitized), CMP+CT corresponds to sensitized and non treated animals; PBSsl corresponds 
to sensitized animal that were treated with PBS as control and the other pictures correspond 
to treated sensitized mice. Results correspond to a single experiment (n=5 per group), which 
is representative of two separate experiments C. Swelling of footpath; difference in thickness 
corresponds to the footpad injected with PBS as control with the contralateral footpad 
injected with CMP in the same mouse. D. CMP-specific serum IgE monitoring during 
sensitization and treatments steps. E. IL-5 in supernatants of spleen cells stimulated with 
CMP or medium for 72h. These results are representative of two independent experiments 
(n=5 per group) with similar results. Data are expressed as means ± SEM. Statistical 
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significance was assessed using ANOVA test (*p<0.05; **p<0.01; ***p<0.001) for 
comparison with sensitized mice (CMP+CT). 
 
Figure 2. Regulatory cytokines and Treg analysis in the intestinal and oral mucosa. A. 
IL-10 and TGF-β protein levels in jejunum were determined by ELISA. B. Representative 
staining of CD25+ FOXP3+ cells gated on CD4+ lymphocytes in the lamina propria by flow 
cytometry. C. Representative staining of CD25+FOXP3+ cells gated on CD4+ lymphocytes in 
SLN and cell frequencies. D. Representative staining of FOXP3+IL-10+ cells gated on 
CD4+CD25+ lymphocytes in SLN and cell frequencies. E. Representative staining of 
CD25+FOXP3+ cells gated on CD4+ lymphocytes in sublingual lamina propria and cell 
frequencies. These results are representative of two independent experiments (n=5 per group) 
with similar results. Data are expressed as means ± SEM. Statistical significance was 
assessed using ANOVA two way (*p<0.05; **p<0.01; ***p<0.001) for comparison with 
sensitized mice (CMP+CT), or Mann-Whitney for comparison between SLIT and combined 
SLIT (# p<0.05).    
 
Figure 3. Analysis of cells in the lamina propria of the buccal and intestinal mucosa.  
Representative staining of CD11c and Class II MHC cells in the lamina propria of the buccal 
mucosa (A) and gut (B) of naïve, control (sensitized) and sensitized/treated mice and 
frequencies. These results are representative of two independent experiments (n=5 per group) 
with similar results. Data are expressed as means ± SEM. Statistical significance was 
assessed using Mann-Whitney test (*p<0.05) for comparison with sensitized mice 
(CMP+CT), or Mann-Whitney for comparison between SLIT and combined SLIT (# p<0.05).    
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure 4. Experimental design and characterization of sorted Treg. A. Schematic 
drawing of experimental protocol in BALB/c mice that received CMP or PBS through the 
sublingual route followed by intraperitoneal IL-2C. B. IL-10 and TGF-β levels in the buccal 
lamina propria by ELISA. C. Purified CD4+ T cells sorted as CD25+CD62L+ or CD25-
CD62L+ cells characterized with IL-10, FOXP3 and α4β7 by flow cytometry. Data are 
expressed as means ± SEM. Statistical significant differences between the groups were 
determined using Mann-Whitney test (*p<0.05). 
Figure 5. In vitro and in vivo functional characterization of sorted cells. A. Representative 
CFSE dilution of labeled CD4+ T cells (1x105) assessed after 4 d of anti-CD3/anti-CD28-
stimulated co-culture with sorted cells (ratios of responder activated-T cells:sorted T cells is 
indicated). B. Capacity of sorted cells to suppress cell proliferation (ratios of responder T 
cells:sorted T cells is indicated). C. Schematic drawing of Treg- adoptive transfer 
experimental protocol (n=4 per group). Naïve mice that were transferred with sorted cells, 
were subsequently sensitized with CMP and CT, and finally challenged intragastrically. D. 
Symptoms scored after the intragastric challenge. E. Skin test and swelling of footpad in the 
different group of mice. Data are expressed as means ± SEM. Statistical significant 
differences between the groups were determined using Mann-Whitney test (*p<0.05; 
**p<0.01).  
 
Supplementary figures 
Figure S1. Diagram of the experimental protocol. Mice received CMPig as control or were 
sensitized with CMP+CTig; intragastric challenges with CMPig were performed to visualize 
and score symptoms; animals were treated with PBSsl as control, CMPsl, PBSsl+IL-2Cip or 
CMPsl+IL-2Cip. The whole experimental protocol was repeated twice with n=5 mice per 
group. 
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